Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Organon & Co. Common Stock (NY:OGN)

9.430 +0.150 (+1.62%)
Official Closing Price Updated: 7:00 PM EDT, Aug 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Organon & Co. Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Organon Reports Results for the Second Quarter Ended June 30, 2022
From Organon & Co.
Via Business Wire
Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate
From Organon & Co.
Via Business Wire
Organon To Report Second Quarter Results and Host Conference Call on August 4, 2022
From Organon & Co.
Via Business Wire
Week In Review: Joincare Plans $300-$400 Million IPO On Swiss Exchange
Joincare Pharmaceutical of Shenzhen plans to list on the SIX Swiss stock exchange, an unusual venue for a China biopharma. The company said it aims to broaden its financing sources and increase global... 
Via Talk Markets
Amphastar's Generic Ganirelix Acetate Injection Scores FDA Approval
 
Via Benzinga
Merck Spinoff Organon Beats Quarterly Views, But Offers Dim Guidance
Organon's sales and earnings fell less than expected, but 2022 sales guidance missed. 
Via Investor's Business Daily
Organon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates
From Organon & Co.
Via Business Wire
On One Year Anniversary, Organon Introduces Global ESG Strategy and Commitments with Publication of Inaugural ESG Report
From Organon & Co.
Via Business Wire
Market Selloff
In a U.S. market selloff, the strong performance of mostly foreign issues was impressive. 
Via Talk Markets
Earnings Scheduled For February 17, 2022
Companies Reporting Before The Bell • Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million. 
Via Benzinga
Organon Easily Beats First-Quarter Expectations Despite Nexplanon Slip-Up
The firm's biggest product sustained a hit due to exchange rates and buying patterns. 
Via Investor's Business Daily
Organon Reports Results for the First Quarter Ended March 31, 2022
From Organon & Co.
Via Business Wire
Organon To Report First Quarter Results and Host Conference Call on May 5, 2022
From Organon & Co.
Via Business Wire
Organon Inks Licensing Pact For Daré Bioscience's Bacterial Vaginosis Treatment
Organon & Co (NYSE: OGN)  
Via Benzinga
Organon Enters into Global License Agreement to Commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis (BV)
From Organon & Co.
Via Business Wire
Healthy Pharma Favorites
Here's a look at two drug makers that we recommend in our Growth & Income Portfolio. The stocks in this portfolio are generally higher-quality, larger-cap companies that have fallen out of favor. 
Via Talk Markets
AbbVie, Alvotech Resolve US Patent Dispute Related To Humira Biosimilar
Alvotech Holdings S.A. has entered into a settlement agreement with AbbVie Inc (NYSE: ABBV), allowing Alvotech to market AVT02 (100 mg/mL), its high-... 
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
World Markets News For Thursday
Ericsson stock lost another 5.27% today in US markets. 
Via Talk Markets
Established Brands Hit Organon's Q4 Sales, Expects FY22 Sales Of Upto $6.4B
Organon & Co's (NYSE: OGN) Q4 FY21 sales decreased 1% to $1.6 billion, beating the consensus of $1.57 billion. Women's Health increased 6%, driven primarily... 
Via Benzinga
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2021
From Organon & Co.
Via Business Wire
Organon Acquires Contraceptive Products, Marvelon® and Mercilon®, in the People’s Republic of China, including Hong Kong and Macau, and Agrees to Acquire these Products in Vietnam
From Organon & Co.
Via Business Wire
Nuclear Winter
Mexico is raising interest rates to 6%, from 5.5%. 
Via Talk Markets
Organon antaa koko henkilökunnalleen vapaapäivän oman terveytensä edistämiseksi kansainvälisenä naisten päivänä
”Koska Covid-19-pandemialla on edelleen suhteettoman suuri vaikutus naisiin, Organon kutsuu muita organisaatioita liittymään joukkoonsa ja olemaan 
Via EIN Presswire
Organon Declares Paid Time Off for All Employees on International Women’s Day; Employees to Focus on Their Own Health in Recognition of Growing Women’s Health Inequity
From Organon & Co.
Via Business Wire
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 17, 2022
From Organon & Co.
Via Business Wire
FDA Accepts Samsung Bioepis’ and Organon’s sBLA for their Citrate-Free, High-Concentration HUMIRA® (Adalimumab) Biosimilar Candidate
From Organon & Co.
Via Business Wire
Organon To Present at the 40th Annual J.P. Morgan Healthcare Virtual Conference
From Organon & Co.
Via Business Wire
Organon Completes Acquisition of Forendo Pharma
From Organon & Co.
Via Business Wire
Warren Buffett Is Selling These Stocks
Looking to make money moves like Warren Buffett? Want to know which stocks Buffett is selling? Interested in finding out why these stock sales might be a huge mistake? 
Via Talk Markets
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.